US EditionThe Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
Sac-TMT uses a novel linker and a belotecan-derivative payload with a 7.4 drug-to-antibody ratio to target TROP2 in advanced solid tumors, aiming to address unmet medical needs globally.
- Kelun-Biotech is developing Sac-TMT, a sacituzumab tirumotecan-like human anti-TROP2 ADC targeting advanced solid tumors including NSCLC, breast, gastric and gynecological tumors.
- Kelun-Biotech's strategy aims to address unmet needs in China and globally, with more than 30 ongoing projects, including one in NDA and over 10 in clinical development.
- The ADC binds TROP2 on tumor cells and Sac-TMT's recombinant anti-TROP2 humanized monoclonal antibodies are endocytosed, releasing KL610023, a topoisomerase I inhibitor, intracellularly and into the tumor microenvironment.
- With marketed ADCs and clinical assets, Kelun-Biotech states it has 4 ADC projects approved for marketing and the OptiDC platform.
- Designed with a high DAR and novel linker, Sac-TMT conjugates a belotecan-derivative payload at a drug-to-antibody ratio of 7.4, while the membrane-permeable KL610023 may enable a bystander effect.
59 Articles
59 Articles
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
/PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab...
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990)'s TROP2...
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 27, 2025 /PRNewswire/ -- On November 25, 2025, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been published…
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 27, 2025 /PRNewswire/ -- On November 25, 2025, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been published…
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 27, 2025 /PRNewswire/ -- On November 25, 2025, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been published…
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 27, 2025 /PRNewswire/ -- On November 25, 2025, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been published…
Coverage Details
Bias Distribution
- 61% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
